



Mary-Ann Warmerdam
Director

Arnold Schwarzenegger
Governor

March 21, 2008

Pesticide Registration and Evaluation Committee

SUBJECT: PRIORITIZATION AND STATUS OF ACTIVE INGREDIENTS FOR RISK CHARACTERIZATION: REPORT 50

The Birth Defect Prevention Act of 1984 (SB 950) requires the California Department of Pesticide Regulation (DPR) to review the toxicology data for all active ingredients currently registered in California.

As part of this review, the active ingredients listed on the attached list were identified as having potential adverse health effects in studies of sufficient quality to permit risk characterization. As a result, these active ingredients will enter the risk characterization process. During this process, DPR staff will identify the seriousness of the adverse effect, determine the expected levels of human exposure, assess the resulting risk to human health, and, if necessary, explore possible mitigation measures.

The results of this risk characterization process will help DPR staff determine if any registration action is warranted. A registration action is not the automatic result for every active ingredient entering the risk characterization process. In addition, as data gaps are filled, other adverse effects might be identified, necessitating another risk characterization. Finally, the risk characterization process should be viewed as a comprehensive evaluation requiring, in some cases, a considerable amount of time. Therefore, it is not possible to predict how long it will take to systematically complete the risk characterization process for each priority category.

The risk characterization document is forwarded to the Assistant Director for approval. When the risk characterization process has been completed, the active ingredient will be removed from this list. Any subsequent risk management activities will be conducted under a separate DPR process.

Attached is a list of active ingredients and the type of corresponding study in which the potential adverse health effects were noted. The active ingredients have been prioritized into High, Moderate, and Low categories. The prioritization of the active ingredients is a subjective process based upon the nature of potential adverse effect, the number of potential adverse effects, the number of species affected, the no observable effect level (NOEL), potential human exposure, use patterns, quantity used, EPA evaluations and actions, etc. In addition, the status of the active ingredients in risk characterization under Senate Bill 950 (Birth Defects Prevention Act), Assembly Bill (AB) 1807 (Toxic Air Contaminant Act), AB 2161 (Food Safety Act), Proposition 65, and new registration submissions are provided in this report.



March 21, 2008

Page 2

Questions about the information contained in this report can be directed to Joyce Gee, Senior Toxicologist in the Medical Toxicology Branch, by telephone at (916) 324-3465, or by e-mail at <jgee@cdpr.ca.gov>.

Sincerely,

Gary Patterson, Ph.D., Chief
Medical Toxicology Branch
(916) 324-3466

Attachment

cc: Joyce Gee

RISK ASSESSMENT PRIORITIZATION LIST

Report # 50

March 21, 2008

The following is a list of the active ingredients that will undergo or are undergoing a risk assessment. The active ingredients have been prioritized into High, Moderate and Low categories. Also listed is the type of toxicity study in which the possible adverse effect(s) was noted.

<u>Active Ingredient</u>	<u>Studies Indicating Possible Adverse Effects</u>
High Priority	
1. Acephate	Genotoxicity study, oncogenicity study, chronic toxicity study, low NOEL
2. Acrolein	Genotoxicity study, chronic toxicity study, oncogenicity study, reproduction study
3. Aldicarb	Low NOEL
4. Arsenic, inorganic	Oncogenicity study (epidemiology), neurotoxicity (epidemiology), genotoxicity study, teratology study
5. Azafenidin	Chronic toxicity study, oncogenicity study, teratology study, reproduction study
6. Bromoxynil	Genotoxicity study, oncogenicity study, teratology study
7. Captan	Genotoxicity study, oncogenicity study
8. Carbaryl	Genotoxicity study, oncogenicity study
9. Chloropicrin	Genotoxicity study, teratology study
10. Chlorothalonil	Combined oncogenicity/chronic toxicity study, oncogenicity study, genotoxicity study
11. Chlorpyrifos	Genotoxicity study, reproduction study
12. Cyfluthrin	Teratology study, reproduction study
13. λ -Cyhalothrin (lambda form)	Chronic toxicity study, oncogenicity study

Changes from previous Report #49 (3/16/2007) are in italics

* new active ingredient

RISK ASSESSMENT PRIORITIZATION LIST

Report # 50

March 21, 2008

14.	2,4-D	Combined oncogenicity/chronic toxicity study, reproduction study, genotoxicity study
15.	Daminozide	Oncogenicity study
16.	Dazomet	Chronic toxicity study, teratology study, genotoxicity study
17.	Diazinon	Genotoxicity study, reproduction study
18.	Dicamba	Neurotoxicity study, chronic toxicity study, oncogenicity study
19.	Dichlobenil	Combined oncogenicity/chronic toxicity study
20.	1,3-Dichloropropene (Telone)	Systemic toxicity/short term exposure
21.	Dicofol	Oncogenicity study, low NOEL, reproduction study
22.	Dimethoate	Genotoxicity study, low NOEL
23.	Disulfoton	Genotoxicity, low NOELs
24.	Emamectin Benzoate	Neurotoxicity in subchronic and chronic studies, reproduction study
25.	Endosulfan	Low NOEL, chronic toxicity study
26.	Ethylene oxide	Combined oncogenicity/chronic toxicity study, oncogenicity study, genotoxicity study
27.	Ethylene thiourea (ETU)	Genotoxicity study, chronic toxicity study, combined oncogenicity/chronic toxicity study
28.	Famoxadone	Chronic toxicity study; genotoxicity study
29.	Fenamiphos	Genotoxicity study, low NOEL
30.	Fenbuconazole	Chronic toxicity study, oncogenicity study, combined oncogenicity/chronic toxicity study, reproduction study, teratology study

Changes from previous Report #49 (3/16/2007) are in italics

* new active ingredient

RISK ASSESSMENT PRIORITIZATION LIST

Report # 50

March 21, 2008

31.	Fenvalerate/Esfenvalerate	Neurotoxicity
32.	Fipronil	Chronic toxicity study, combined chronic toxicity/oncogenicity study
33.	Flonicamid	Oncogenicity
34.	Flumioxazin	Chronic toxicity study, reproduction study, teratology study
35.	Glufosinate ammonium	Chronic toxicity study, teratology study
36.	Glutaraldehyde	Genotoxicity study, subchronic toxicity study, combined toxicity study
37.	Imazalil	Teratology study
38.	Indoxacarb	Subchronic toxicity studies, combined chronic toxicity/oncogenicity study, chronic toxicity study, oncogenicity study, neurotoxicity study
39.	Iprodione	Genotoxicity study, chronic toxicity studies, oncogenicity study
40.	Linuron	Combined oncogenicity/chronic toxicity study, oncogenicity study, chronic toxicity study, reproduction study
41.	Mancozeb	Genotoxicity study, chronic toxicity study (also see ETU)
42.	Methiocarb	Teratology study
43.	Methyl parathion	Reproduction study, teratology study, genotoxicity study, chronic toxicity study
44.	Metofluthrin	Oncogenicity, neurotoxicity
45.	Milbemectin	Reproduction study, neurotoxicity study, subchronic toxicity study
46.	N-octylbicycloheptene dicarbomixide (MGK-264)	Oncogenicity study

Changes from previous Report #49 (3/16/2007) are in italics

* new active ingredient

RISK ASSESSMENT PRIORITIZATION LIST

Report # 50

March 21, 2008

47.	Novaluron	Chronic toxicity
48.	Orthophenylphenol	Genotoxicity study, oncogenicity study, teratology study
49.	Oxadiazon	Chronic toxicity study, oncogenicity study, genotoxicity study, teratology study
50.	Oxydemeton-methyl	Reproduction study, genotoxicity study
51.	Paradichlorobenzene	Oncogenicity study, reproduction study, genotoxicity study
52.	Paraquat dichloride	Genotoxicity study, oncogenicity study, combined oncogenicity/chronic toxicity study, chronic toxicity study
53.	PCNB	Genotoxicity study, oncogenicity studies
54.	Profenofos	Low NOEL, chronic toxicity study
55.	Propanil	Combined oncogenicity/chronic toxicity study, chronic toxicity study, oncogenicity study
56.	Propargite	Reproduction study, genotoxicity study, combined oncogenicity/chronic toxicity study
57.	Propylene oxide	Genotoxicity study, oncogenicity study
58.	Propyzamide	Oncogenicity study
59.	Pyraclostrobin	Subchronic toxicity study, low NOEL's in teratology , chronic and reproduction studies
60.	Sodium tertathiocarbonate (CS ₂)	Multiple toxicity studies
61.	Spirodiclofen	Chronic dog, rat and mouse oncogenicity, Rat reproduction
62.	Spiromesifin	Low NOELs
63.	<i>Spirotetramat*</i>	<i>Chronic and oncogenicity</i>
64.	Sulfentrazone	Chronic rat, reproductive effects, rat Developmental toxicity

Changes from previous Report #49 (3/16/2007) are in italics

* new active ingredient

RISK ASSESSMENT PRIORITIZATION LIST

Report # 50

March 21, 2008

65.	Tebuconazole	Teratology study
66.	Thiacloprid	Oncogenicity, reproductive toxicity
67.	Thiazopyr	Subchronic toxicity study, combined oncogenicity /chronic toxicity study
68.	Thiophanate-methyl	Oncogenicity studies, chronic toxicity studies
69.	Tralkoxydim	Chronic toxicity study, combined toxicity study, teratology study
70.	Triadimefon	Teratology study, oncogenicity study, reproduction study, chronic toxicity study
71.	Triallate	Oncogenicity study, chronic toxicity study, genotoxicity study
72.	Tributyltin benzoate	Developmental toxicity study, oncogenicity study
73.	Trifloxysulfuron-sodium	Neurotoxicity study
74.	Vinclozolin	Chronic toxicity study, teratology study, genotoxicity study, reproduction study
75.	Ziram	Oncogenicity study, reproduction study, genotoxicity study

Moderate Priority

1.	Acequinocyl	Chronic toxicity study, reproduction study
2.	Acetamiprid	Subchronic and chronic toxicity studies
3.	Acibenzolar-s-methyl	Combined chronic toxicity/oncogenicity study, teratology study, genotoxicity study, chronic toxicity study, subchronic toxicity study
4.	Alkyldimethyl benzyl ammonium chloride	Teratology study

Changes from previous Report #49 (3/16/2007) are in italics

* new active ingredient

RISK ASSESSMENT PRIORITIZATION LIST

Report # 50

March 21, 2008

5.	Azoxystrobin	Teratology study
6.	Bensulide	Chronic toxicity study, low NOEL, delayed neurotoxicity study
7.	Bentazon, sodium salt	Teratology study, oncogenicity study
8.	Bifenazate	Chronic toxicity study, combined toxicity study
9.	Boric acid	Chronic toxicity study, teratology study
10.	Boscalid (BAS510F)	Oncogenicity study
11.	Bromacil	Oncogenicity study, genotoxicity study
12.	Buprofezin	Subchronic toxicity study, chronic toxicity study, combined toxicity study, teratology study
13.	Cacodylic acid	Genotoxicity study, chronic toxicity study, oncogenicity study, teratology study
14.	Carboxin	Genotoxicity study, oncogenicity study, chronic toxicity study
15.	Chlorflurenol, methyl ester	Chronic toxicity study, teratology study
16.	Chlorthal-dimethyl	Combined oncogenicity/chronic toxicity study, oncogenicity study
17.	Clomazone	Chronic toxicity study, teratology study
18.	Clothianidin	Genotoxicity, neurotoxicity (subchronic study)
19.	Cryolite	Oncogenicity study
20.	Cyanuric acid, monosodium salt	Combined oncogenicity/chronic toxicity study
21.	Cyclanilide	Combined oncogenicity/chronic toxicity study
22.	Cymoxanil	Genotoxicity study, chronic toxicity study, teratology study

Changes from previous Report #49 (3/16/2007) are in italics

* new active ingredient

RISK ASSESSMENT PRIORITIZATION LIST

Report # 50

March 21, 2008

23.	Cypermethrin	Chronic toxicity studies, oncogenicity study, reproduction study
24.	Cyphenothrin	Neurotoxicity
25.	Cyprodinil	Subchronic toxicity study, combined oncogenicity/chronic toxicity study
26.	2,4-DB [4-(2,4-dichloro-phenoxy)butyric acid]	Genotoxicity studies, reproduction study
27.	Dichloran/Dicloran	Genotoxicity study, chronic toxicity study, reproduction study
28.	Didecyldimethyl-ammonium chloride	Low NOEL
29.	N,N-Diethyl-2-(4-methylbenzyloxy)-ethylamine Hydrochloride (PT807-HCL)	Subchronic toxicity study, chronic toxicity studies
30.	Difenacoum	Genotoxicity, chronic effects
31.	Difenoconazole	Teratology studies, combined oncogenicity/chronic toxicity study
32.	Difethialone	Low NOEL (acute, subchronic)
33.	Dimethenamid-P	Rat oncogenicity/chronic toxicity, low NOEL
34.	Dimethomorph	Oncogenicity study, chronic toxicity study, genotoxicity study
35.	O,O-Dimethyl O-(4-nitro-M-tolyl)-phosphorothioate (Sumithion)	Low NOEL (subchronic study), oncogenicity study, reproduction study
36.	Dinotefuran	Reproduction study, chronic toxicity study, subchronic toxicity study
37.	Diphenylamine	Combined chronic toxicity/oncogenicity study

Changes from previous Report #49 (3/16/2007) are in italics

* new active ingredient

RISK ASSESSMENT PRIORITIZATION LIST

Report # 50

March 21, 2008

38.	Dipropyl iso-cinchomeronate (MGK-326)	Oncogenicity studies
39.	Dithiopyr	Subchronic toxicity studies
40.	Diuron	Genotoxicity study, oncogenicity studies
41.	Dodine	Oncogenicity study
42.	Endothall	Chronic toxicity study, oncogenicity study
43.	Esbiothrin	Genotoxicity study, reproduction study
44.	Ethalfuralin	Chronic toxicity study, genotoxicity study, combined oncogenicity/chronic toxicity study
45.	Ethofumesate	Teratology study
46.	Etoxazole	Genotoxicity study
47.	Fenarimol	Combined oncogenicity/chronic toxicity study
48.	<i>Flubendiamide*</i>	<i>Chronic effects in multiple studies</i>
49.	Fludioxonil	Combined oncogenicity/chronic toxicity study, subchronic toxicity study
50.	<i>Fluopicolide*</i>	<i>Oncogenicity and liver changes</i>
51.	<i>Fluoxastrobin*</i>	<i>Oncogenicity</i>
52.	Fluroxypyr	Chronic toxicity study, subchronic toxicity study
53.	Flurprimidol	Chronic toxicity study, teratology study, reproduction study
54.	τ -Fluvalinate (tau form)	Genotoxicity study, reproduction study, teratology study, chronic toxicity study
55.	Forchlorfenuron	Genotoxicity study
56.	Formaldehyde	Genotoxicity study, oncogenicity study

Changes from previous Report #49 (3/16/2007) are in italics

* new active ingredient

RISK ASSESSMENT PRIORITIZATION LIST

Report # 50

March 21, 2008

57.	Halosulfuron	Chronic toxicity study
58.	Hexahydro-1,3,5-triethyl-S-triazine	Teratology study
59.	Hexythiazox	Oncogenicity study
60.	(Hydroxymethyl)phosphonium sulfate (Tetrakis)	Teratology study
61.	Imidacloprid	Combined oncogenicity/chronic toxicity study, teratology study, genotoxicity study
62.	Imiprothrin	Teratology study, neurotoxicity study, chronic toxicity study, genotoxicity study
63.	Isoxaben	Oncogenicity studies, genotoxicity study
64.	Kresoxim-methyl	Combined chronic toxicity/oncogenicity study
65.	MCPA	Genotoxicity study
66.	Mecoprop (MCP)	Oncogenicity study, genotoxicity study
67.	Mefenoxam	Genotoxicity study
68.	Mefluidide, diethanolamine salt	Combined oncogenicity/chronic toxicity study, oncogenicity study, chronic toxicity study
69.	Metaflumizone	Genotoxicity
70.	Metalaxyl	Genotoxicity study
71.	Methomyl	Oncogenicity study, chronic toxicity study
72.	Methoxyfenozide	Chronic toxicity study, combined toxicity study, reproduction study
73.	Metribuzin	Chronic toxicity study
74.	MSMA/MAA	Combined oncogenicity/chronic toxicity study

Changes from previous Report #49 (3/16/2007) are in italics

* new active ingredient

RISK ASSESSMENT PRIORITIZATION LIST

Report # 50

March 21, 2008

75.	Napropamide	Combined oncogenicity/chronic toxicity study, genotoxicity study
76.	Napthalene acetic acid	Reproduction study, teratology study, chronic toxicity study, combined toxicity study
77.	Norflurazon	Chronic toxicity study
78.	Noviflumuron (XDE-007)	Reproduction study
79.	Ortho-benzyl-para-chlorophenol	Teratology study
80.	Oryzalin	Oncogenicity study, chronic toxicity study
81.	Oxyfluorfen	Genotoxicity study, oncogenicity study, teratology study
82.	Oxythioquinox	Chronic toxicity study, reproduction study, teratology study, genotoxicity study
83.	Pebulate	Combined oncogenicity/chronic toxicity study, chronic toxicity study
84.	Penoxsulam	Oncogenicity
85.	Permethrin	Reproduction study, chronic toxicity study, oncogenicity study
86.	Phenol	Oncogenicity studies
87.	Phenothrin	Oncogenicity study, reproduction toxicity study
88.	Phorate	Low NOEL
89.	Picaridin (KBR 3023)	Subchronic toxicity, genotoxicity
90.	Picloram	Combined chronic toxicity/oncogenicity study
891.	Polyhexamethylene biguanidine (Baqvacil)	Teratology study
92.	Prallethrin (ETOC)	Subchronic toxicity study, chronic toxicity study, teratology study

Changes from previous Report #49 (3/16/2007) are in italics

* new active ingredient

RISK ASSESSMENT PRIORITIZATION LIST

Report # 50

March 21, 2008

93.	Prometon	Low NOEL
94.	Propiconazole	Low NOEL, chronic toxicity study
95.	Pymetrozine	Combined oncogenicity/chronic toxicity study, oncogenicity study, acute neurotoxicity study
96.	Pyraflufen-ethyl	Chronic toxicity study, oncogenicity study, genotoxicity study
97.	Pyrethrins	Reproduction study, genotoxicity study, oncogenicity study
98.	Pyridaben	Low NOEL
99.	Pyridate	Chronic toxicity study
100.	Pyrimethanil	Oncogenicity
101.	Pyriproxyfen	Chronic toxicity study
102.	Pyriproxyfen-sodium	Combined chronic toxicity/oncogenicity study
103.	Quinclorac	Chronic toxicity study; genotoxicity study
104.	Resmethrin	Teratology study, oncogenicity study, chronic toxicity study, reproduction study
105.	Rimsulfuron	Chronic toxicity studies
106.	Simazine	Combined oncogenicity/chronic toxicity study
107.	<i>Spinetoram*</i>	<i>Chronic toxicity</i>
108.	Spinosad	Chronic toxicity study, combined chronic toxicity/oncogenicity study
109.	Sulfosulfuron	Chronic toxicity, oncogenicity
110.	TCMTB	Oncogenicity study

Changes from previous Report #49 (3/16/2007) are in italics

* new active ingredient

RISK ASSESSMENT PRIORITIZATION LIST

Report # 50

March 21, 2008

111.	Tebufenozide	Chronic toxicity studies
112.	Terbutylazine (Bellacide)	Low NOEL
113.	Tetrachlorvinphos	Oncogenicity study, genotoxicity study
114.	<i>Tetraconazole*</i>	<i>Oncogenicity (sugarbeets only use)</i>
115.	Thiamethoxam	Combined chronic toxicity/oncogenicity study, chronic toxicity study, oncogenicity study
116.	Thiodicarb	Oncogenicity study, reproduction study, genotoxicity study
117.	Thiram	Low NOEL, teratology study, chronic toxicity study, combined oncogenicity/chronic toxicity study
118.	Trichlorfon	Combined chronic toxicity/oncogenicity study, genotoxicity study
119.	Triclopyr	Genotoxicity study, low NOEL
120.	Trifloxystrobin	Oncogenicity study, chronic toxicity study, genotoxicity study
121.	Triflumizole	Chronic toxicity study
122.	Trifluralin	Combined oncogenicity/chronic toxicity study, oncogenicity study
123.	Triforine	Teratology study, oncogenicity study
124.	Tris (hydroxymethyl nitromethane)	Genotoxicity study, teratology study
125.	Trisulfuron-methyl	Chronic toxicity study, oncogenicity study
126.	Uniconazole-P	Chronic toxicity study, oncogenicity study, genotoxicity study, low NOEL
127.	Zinc 2-Pyridinethiol-1-oxide (<i>omadine</i>)	Teratology studies

Changes from previous Report #49 (3/16/2007) are in italics

* new active ingredient

RISK ASSESSMENT PRIORITIZATION LIST

Report # 50

March 21, 2008

Low Priority

1.	Alachlor	Oncogenicity study, chronic toxicity study, low NOEL
2.	Alpha-isoctadecyl-omega-hydroxy-poly(oxyethylene)	None identified
3.	Aminopyralid	Chromosome aberrations
4.	4-t-Amylphenol (Para-tert-amylphenol)	None identified
5.	Azadirachtin	None identified
6.	Bacillus subtilis	None identified
7.	Bacillus thuringiensis	None identified
8.	Beauveria bassiana	None identified
9.	Benefin	Combined chronic toxicity/oncogenicity study
10.	Benzyl benzoate	None identified
11.	Bronopol	Chronic toxicity study, low NOEL
12.	Butylate	Genotoxicity study, neurotoxicity study
13.	N-Butyl-1,2-benzisothiazole-3-one	Genotoxicity
14.	Carfentrazone-ethyl	Chronic toxicity studies
15.	Chlorhexidine diacetate	Dermal (local) effects
16.	1-(3-Chloroallyl)-3,5,7-triazadiazolopyridine	Genotoxicity study, teratology study
17.	4-Chloro-3,5-xyleneol	Genotoxicity study
18.	Chlorpropham	Genotoxicity study
19.	Chlorsulfuron	Chronic toxicity study
20.	Clethodim	Genotoxicity study

Changes from previous Report #49 (3/16/2007) are in italics

* new active ingredient

RISK ASSESSMENT PRIORITIZATION LIST

Report # 50

March 21, 2008

21.	Clopyralid	Subchronic toxicity study; combined oncogenicity/chronic toxicity study
22.	<i>Cyazofamid*</i>	<i>Body and organ weight effects</i>
23.	N-Cyclopropyl-N'-(1,1,-dimethylethyl)-6-(methylthio)-1,3,5-triazine-2,4-diamine (Irgarol)	None identified
24.	2,4-DP	Combined oncogenicity/chronic toxicity study
25.	Desmediphan	Genotoxicity study, teratology study
26.	1,2-Dibromo-2,4-dicyanobutane (Tektamer 38)	Subchronic toxicity study
27.	4,5-Dichloro-2-noctyl-3(2H)-isothiazolone (Sea-Nine)	Antimicrobial; local corrosive effects
28.	Dichlorprop-p	Chronic toxicity studies
29.	Difenzoquat methyl sulfate	Chronic toxicity study
30.	Diflufenzopyr	Teratology study, reproduction study
31.	Dimethipin	Chronic toxicity study
32.	Dimethoxane	Oncogenicity study, genotoxicity study
33.	5,5-Dimethylhydantoin	Chronic toxicity studies
34.	4,4-Dimethyloxazolidine	Genotoxicity study
35.	Ethephon	Genotoxicity study
36.	Fenamidone	Chronic toxicity studies, genotoxicity studies
37.	Fenhexamid	Subchronic and chronic toxicity studies
38.	Flumiclorac-pentyl	Chromosome aberrations
39.	Fluridone	Chronic toxicity study, oncogenicity study

Changes from previous Report #49 (3/16/2007) are in italics

* new active ingredient

RISK ASSESSMENT PRIORITIZATION LIST

Report # 50

March 21, 2008

40.	Flutolonil	Genotoxicity study, combined oncogenicity/ chronic toxicity study
41.	Foramsulfuron	Genotoxicity study
42.	Formetanate hydrochloride	Genotoxicity study
43.	Fosetyl-Al	Combined oncogenicity/chronic toxicity study
44.	Gliocladium verens	None identified
45.	Glyphosate	Oncogenicity studies
46.	Halofenozide	Teratology study, subchronic toxicity study
47.	Hexazinone	Genotoxicity study
48.	Hydroprene	Chronic toxicity study, oncogenicity study
49.	5-Hydroxymethyl-1-aza-3,7- dioxabicyclo-(3,3,0)octane	Genotoxicity study
50.	Imazamethabenz	Subchronic toxicity study, combine chronic toxicity/oncogenicity study
51.	Imazamox	Teratology studies
52.	Imazapic	Chronic toxicity study
53.	Imazapyr	Teratology study
54.	Imazethapyr	Genotoxicity study, teratology study
55.	Intersept (for chemical details, see chemicals 3836, 3837, 3838)	Teratology study
56.	Maleic hydrazide	Genotoxicity study
57.	Maneb (also see ETU-High Priority)	Genotoxicity study
58.	Mepiquat chloride	Chronic toxicity studies
59.	Mesosulfuron-methyl	Subchronic toxicity study

Changes from previous Report #49 (3/16/2007) are in italics

* new active ingredient

RISK ASSESSMENT PRIORITIZATION LIST

Report # 50

March 21, 2008

60.	Metaldehyde	Chronic toxicity study
61.	Methylene bis(thiocyanate)	Genotoxicity study
62.	Metolachlor	Oncogenicity study, chronic toxicity study
63.	Nicosulfuron (Accent)	None identified
64.	Nithiazine	Neurotoxicity study
65.	Nitrapyrin	Combined oncogenicity/chronic toxicity study
66.	4-(2-Nitrobutyl) morpholine/ 4,4'-(2-ethyl-2-nitrotrimethylene) morpholine	Genotoxicity study
67.	Octhilinone	Genotoxicity study
68.	<i>Orthosulfamuron*</i>	<i>Oncogenicity and chronic liver changes</i>
69.	Oxamyl	Chronic toxicity study
70.	Oxazolidine E (Bioban)	Teratology study
71.	Parachlorometacresol	Antimicrobial; local irritant
72.	Pendimethalin	Oncogenicity study
73.	Phenmedipham	None identified; incomplete data base
74.	Piperonyl butoxide	Oncogenicity study
75.	Prodiamine	Teratology study, genotoxicity study
76.	Prohexadione calcium	Chronic toxicity study, genotoxicity study
77.	Prometryn	None identified
78.	Propoxycarbazone-sodium	None identified
79.	Pseudomonas cepacia (Blue Circle)	None identified
80.	Pseudomonas fluorescens (Frostban A&B)	None identified

Changes from previous Report #49 (3/16/2007) are in italics

* new active ingredient

RISK ASSESSMENT PRIORITIZATION LIST

Report # 50

March 21, 2008

81.	Pseudomonas syringae	None identified
82.	Pyrazon	Chronic toxicity studies
83.	Rotenone	Genotoxicity study
84.	Sethoxydim	Teratology study, chronic toxicity study
85.	Siduron	Oncogenicity study
86.	Sodium hydroxymethyl glycinate	None identified
87.	Streptomyces griseoviridis (Mycostop)	None identified
88.	Tebuthiuron	Reproduction study, teratology study, mutagenicity study
89.	Tetramethrin	Reproduction study, oncogenicity study, teratology study
90.	Thiobencarb	Genotoxicity study
91.	Trinexapac-ethyl (Cimectacarb)	Combined oncogenicity/chronic toxicity study

CHANGES TO THE RISK ASSESSMENT PRIORITIZATION LIST

A. Changes in Status of Active Ingredients Already on Prioritization List

ETU (diet) Approved by Assistant Director (1/17/2008)

Mancozeb (diet) Approved by Assistant Director (1/17/2008)

Maneb (diet) Approved by Assistant Director (1/17/2008)

B. Active Ingredients Removed from Prioritization List ^a (0)

C. Active Ingredients Added to Prioritization List (8)

Cyazofamid Low

Flubendiamide Moderate

Fluopicolide Moderate

Fluoxastrobin Moderate

Orthosulfamuron Low

Spinetoram Moderate

Spirotetramat High

Tetraconazole Moderate

a/ A completed risk assessment must be approved by Assistant Director before it can be removed from the PREC prioritization list

Changes from previous Report #49 (3/16/2007) are in italics

* new active ingredient

RISK ASSESSMENT PRIORITIZATION LIST

Report # 50

March 21, 2008

STATUS OF ACTIVE INGREDIENTS CURRENTLY IN RISK ASSESSMENT

Note: The following list only includes those active ingredients that are currently in risk assessment. It does not include the active ingredients in risk mitigation/risk management. Once the risk assessment for a specific active ingredient has been completed and approved by the Assistant Director, that active ingredient is removed from the SB-950/PREC Prioritization List. In addition to conducting a risk assessment under SB-950 for occupational and residential exposures, many risk assessments contain a dietary component under AB-2161 and an air component under AB-1807. Whenever possible, these components are included in one, comprehensive risk characterization document.

The following stages of the risk assessment process are included in this status section:

Hazard Identification Stage: includes the development of the Toxicology Profile Section and the selection of the definitive studies, critical endpoints and NOEL/LOEL/oncogenicity potency values that will be used for risk characterization. Responsibility: Medical Toxicology Branch.

Exposure Assessment Stage: includes the development of occupational, residential, dietary (food/water), ambient air and off-site air exposure scenarios. Responsibility: Worker Health and Safety Branch for occupational, residential and air. Medical Toxicology Branch for dietary.

Risk Characterization Stage: includes the development of quantitative values used to assess the risk from critical NOELs/oncogenic potency factors and exposure values. Responsibility: Medical Toxicology Branch

Review Stage: includes the review of the final draft of the Risk Characterization Document within DRP and externally by OEHHA, US EPA and other interested parties. Also includes development of DPR response to reviewers comments.

Approval Stage: completed Risk Characterization Document awaiting approval by Assistant Director.

Orthophenylphenol – Approval stage

Inactive : No current risk assessment activities because of higher priorities.

- . Paraquat-- Hazard identification stage - inactive
- Propyzamide - Inactive

RISK ASSESSMENT PRIORITIZATION LIST

Report # 50

March 21, 2008

Active Ingredients

1. *Acephate – Risk characterization stage*
2. Acrolein – Hazard identification stage
3. Carbaryl – *Risk characterization stage (diet)*
4. Chloropicrin – Hazard identification and exposure assessment stages
5. *Chlorothalonil – Risk characterization stage (occupational/air)*
6. Chlorpyrifos - Review stage (occupational/air)
7. Cyfluthrin – Hazard identification phase
8. 1,3-dichloropropene (Telone) – Risk characterization phase (acute, air)
9. Endosulfan – Approval stage
10. Esfenvalerate – Hazard identification stage
11. Fipronil - Hazard identification and exposure assessment stages
12. Indoxacarb– Hazard identification and exposure assessment stages
13. Methomyl – Hazard identification stage (dietary)
14. Methyl iodide- Hazard identification and exposure assessment stages
15. Methyl parathion – Risk characterization stage (occupational)
16. Paradichlorobenzene – Hazard identification stage
17. Phosphine – Hazard identification stage
18. Propargite – *Risk characterization stage (occupational)*
19. Simazine - Hazard identification and exposure assessment stages
20. Sodium tetrathiocarbonate - Hazard identification and exposure assessment stages

Changes from previous Report #49 (3/16/2007) are in italics

* new active ingredient